Business
Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
CRAYON summary
CNBC reports that Novartis has raised its peak sales forecasts for its blockbuster drugs to $18 billion as the drugmaker seeks to show its growth can last. According to CNBC, the company cited strong demand as it upgraded forecasts for its multiple sclerosis, leukemia and cholesterol medicines.
Based on CNBC's report - only one outlet has covered this so far. Read the original.▲ Sign in to vote stories up
Coverage 1 source · 1 report
Chronological.
-
Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
Discussion 0 comments